Drugs › Histamine-1 receptor antagonist
Generic name
Hydrocodone polistirex and chlorpheniramine polistirex: adverse event reports filed with FDA
950 reports list it as a suspect or interacting product, 2017–2026. Class: Histamine-1 receptor antagonist.
- 950
- reports as suspect product
- 0% of all reports · about 106 a year
- 8
- reports, 12 months to June 2026
- 13 in the 12 months before
- 95.7%
- marked serious by the reporter
- 57.7% across the class
- 20.5%
- record death among outcomes, as reported
- 195 reports · not verified by FDA
950 adverse event reports received by FDA list hydrocodone polistirex and chlorpheniramine polistirex, a generic name as a suspect or interacting product, from July 2017 to June 2026. A further 23 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 8 reports listed it, down 38% from 13 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 106 reports a year and 0% of the 20,646,523 reports in the database, and 0.7% of the reports for the histamine-1 receptor antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded dependence (86.8%), overdose (48.4%) and death (19.3%). A report can list several reactions, so shares add to more than 100%; 96 different terms appear across these reports. Dependence is recorded in 86.8% of these reports, with no counterpart in the median histamine-1 receptor antagonist drug (0%).
95.7% of the reports are marked serious by the reporter (57.7% across the class); 20.5% record death among the outcomes and 0.5% record hospitalisation, as reported. 98.6% of the reports came from consumers, and the largest patient age group is 45 to 64 (0.6%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Hydrocodone polistirex and chlorpheniramine polistirex reports recording the termmedian drug in histamine-1 receptor antagonist
- Dependence86.8%825
- Overdosea dose above the recommended amount48.4%460
- Deaththe patient died; cause not stated by this term19.3%183
- Depressionlow mood4.9%47
- Ill-defined disordera condition that was not clearly described4.3%41
- Withdrawal syndrome3.7%35
- Anxietyanxiety3.4%32
- Suicide attempta suicide attempt1.8%17
- Amnesiamemory loss1.1%10
- Constipationconstipation1.1%10
- Painpain, site not specified0.9%9
- Confusional stateconfusion0.8%8
- Disability0.8%8
- Maternal exposure during pregnancythe mother took the medicine during pregnancy0.8%8
- Foetal exposure during pregnancythe unborn baby was exposed to the medicine0.7%7
- Brain injury0.6%6
- Cardiac disorder0.6%6
- Dizzinesslight-headedness or unsteadiness0.6%6
- Hyperaesthesia0.6%6
- Mental disorder0.6%6
- Myocardial infarctionheart attack0.6%6
- Nauseafeeling sick0.6%6
- Suicidal ideationthoughts of suicide0.6%6
- Tooth loss0.6%6
- Completed suicidedeath by suicide0.5%5
- Hepatitis Chepatitis C infection0.5%5
- Insomniadifficulty sleeping0.5%5
Top 30 of 96 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 34 drugs in the histamine-1 receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 135,666 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Pain | 8 | 0.8% |
| Cough | 4 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 950 reports.
In context
| Measure | Hydrocodone polistirex and chlorpheniramine polistirex | Histamine-1 receptor antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 950 | 135,666 | 20,646,523 |
| Share of that pool | — | 0.7% | 0% |
| Reports, latest 12 months | 8 | — | 1,332,454 |
| Marked serious | 95.7% | 57.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 205 | 190 | 91 |
| Hospitalisation recorded, per 1,000 reports | 5 | 203 | 213 |
| Consumer-filed share | 98.6% | 50.8% | 45.8% |
| Top term, share of reports | Dependence 86.8% | median 0% | 0.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the histamine-1 receptor antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Zyrtec | brand | 20,342 | 929 | 16.7% |
| Cetirizine hydrochloride | generic | 19,092 | 2,043 | 77.5% |
| Diphenhydramine | generic | 15,339 | 1,157 | 96% |
| Cetirizine | generic | 12,522 | 1,548 | 91.7% |
| Benadryl | brand | 9,612 | 432 | 66.6% |
| Allegra Allergy | brand | 7,868 | 304 | 3.6% |
| Diphenhydramine hydrochloride | generic | 5,556 | 538 | 94.6% |
| Xyzal Allergy 24HR | brand | 5,302 | 147 | 3.3% |
| Cetirizine hydrochloride, pseudoephedrine hydrochloride | generic | 4,914 | 909 | 99.3% |
| Xyzal | brand | 3,824 | 181 | 44.6% |
| Fexofenadine | generic | 3,142 | 335 | 62.5% |
| Diphenhydramine hcl | generic | 2,741 | 0 | 91% |
| Desloratadine | generic | 2,699 | 190 | 93.6% |
| Azelastine hydrochloride | generic | 2,502 | 151 | 5.7% |
| Aleve PM | brand | 1,877 | 13 | 6.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Hydrocodone polistirex and chlorpheniramine polistirex reports
How many adverse event reports has FDA received for Hydrocodone polistirex and chlorpheniramine polistirex?
950 reports list Hydrocodone polistirex and chlorpheniramine polistirex as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 8 of them arrived in the latest 12 months. Another 23 list it only as a concomitant medication.
What reactions are recorded in Hydrocodone polistirex and chlorpheniramine polistirex reports?
dependence (86.8%), overdose (48.4%), death (19.3%), depression (4.9%) and ill-defined disorder (4.3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Hydrocodone polistirex and chlorpheniramine polistirex was responsible.
How serious are the reports?
95.7% are marked serious by the reporter. Among the outcomes recorded, 20.5% of reports include death and 0.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (98.6%), pharmacist (0.5%) and other health professional (0.5%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Hydrocodone polistirex and chlorpheniramine polistirex rising?
8 reports in the 12 months to June 2026, down 38% from 13 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Hydrocodone polistirex and chlorpheniramine polistirex was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Hydrocodone polistirex and chlorpheniramine polistirex?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Hydrocodone polistirex and chlorpheniramine polistirex as a suspect or interacting product; reports listing it only as a concomitant medication (23) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.